These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 15076165)
21. Safety and efficacy of eprosartan, a new angiotensin II receptor blocker. Shusterman NH Am Heart J; 1999 Sep; 138(3 Pt 2):238-45. PubMed ID: 10467219 [TBL] [Abstract][Full Text] [Related]
22. Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension. Puig JG; Mateos F; Buño A; Ortega R; Rodriguez F; Dal-Ré R J Hypertens; 1999 Jul; 17(7):1033-9. PubMed ID: 10419078 [TBL] [Abstract][Full Text] [Related]
25. Carvedilol prevents severe hypertensive cardiomyopathy and remodeling. Barone FC; Campbell WG; Nelson AH; Feuerstein GZ J Hypertens; 1998 Jun; 16(6):871-84. PubMed ID: 9663928 [TBL] [Abstract][Full Text] [Related]
26. Exercise and cardiovascular outcomes in hypertensive patients in relation to structure and function of left ventricular hypertrophy: the LIFE study. Boman K; Gerdts E; Wachtell K; Dahlöf B; Nieminen MS; Olofsson M; Papademetriou V; Devereux RB Eur J Cardiovasc Prev Rehabil; 2009 Apr; 16(2):242-8. PubMed ID: 19369828 [TBL] [Abstract][Full Text] [Related]
27. Once-daily eprosartan mesylate in the treatment of elderly patients with isolated systolic hypertension: data from a 13-week double-blind, placebo-controlled, parallel, multicenter study. Punzi HA; Punzi CF J Hum Hypertens; 2004 Sep; 18(9):655-61. PubMed ID: 15042114 [TBL] [Abstract][Full Text] [Related]
28. Attenuation of cardiac failure, dilatation, damage, and detrimental interstitial remodeling without regression of hypertrophy in hypertensive rats. Tsotetsi OJ; Woodiwiss AJ; Netjhardt M; Qubu D; Brooksbank R; Norton GR Hypertension; 2001 Oct; 38(4):846-51. PubMed ID: 11641297 [TBL] [Abstract][Full Text] [Related]
29. Effects of eprosartan versus hydrochlorothiazide on markers of vascular oxidation and inflammation and blood pressure (renin-angiotensin system antagonists, oxidation, and inflammation). Rahman ST; Lauten WB; Khan QA; Navalkar S; Parthasarathy S; Khan BV Am J Cardiol; 2002 Mar; 89(6):686-90. PubMed ID: 11897210 [TBL] [Abstract][Full Text] [Related]
30. Cardiac overexpression of monocyte chemoattractant protein-1 in transgenic mice prevents cardiac dysfunction and remodeling after myocardial infarction. Morimoto H; Takahashi M; Izawa A; Ise H; Hongo M; Kolattukudy PE; Ikeda U Circ Res; 2006 Oct; 99(8):891-9. PubMed ID: 16990567 [TBL] [Abstract][Full Text] [Related]
31. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Solomon SD; Appelbaum E; Manning WJ; Verma A; Berglund T; Lukashevich V; Cherif Papst C; Smith BA; Dahlöf B; Circulation; 2009 Feb; 119(4):530-7. PubMed ID: 19153265 [TBL] [Abstract][Full Text] [Related]
32. Amlodipine and atorvastatin improved hypertensive cardiac hypertrophy through regulation of receptor activator of nuclear factor kappa B ligand/receptor activator of nuclear factor kappa B/osteoprotegerin system in spontaneous hypertension rats. Lu J; Liu F; Liu D; Du H; Hao J; Yang X; Cui W Exp Biol Med (Maywood); 2016 Jun; 241(11):1237-49. PubMed ID: 26908571 [TBL] [Abstract][Full Text] [Related]
33. Temporal regression of myocyte hypertrophy in hypertensive, heart failure-prone rats treated with an AT1-receptor antagonist. Tamura T; Said S; Andersen SM; McCune SA; Mochizuki S; Gerdes AM J Card Fail; 2002 Feb; 8(1):43-7. PubMed ID: 11862582 [TBL] [Abstract][Full Text] [Related]
34. Angiotensin II-induced cardiomyocyte hypertrophy and cardiac fibrosis in stroke-prone spontaneously hypertensive rats. Ikeda Y; Nakamura T; Takano H; Kimura H; Obata JE; Takeda S; Hata A; Shido K; Mochizuki S; Yoshida Y J Lab Clin Med; 2000 Apr; 135(4):353-9. PubMed ID: 10779052 [TBL] [Abstract][Full Text] [Related]
35. [Effect of total flavonoids of Hippophae rhamnoides L. on the expression of MCP-1 in aorta of spontaneously hypertensive rats]. He J; Chen Y; Xiao HY; Chang BB; Ding QF; Zhang MS; Zeng Z; Zhang XJ Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 May; 40(3):481-5. PubMed ID: 19627010 [TBL] [Abstract][Full Text] [Related]
36. Pharmacological mechanism of angiotensin II receptor antagonists: implications for the treatment of elevated systolic blood pressure. Brooks DP; Ruffolo RR J Hypertens Suppl; 1999 Jun; 17(2):S27-32. PubMed ID: 10465064 [TBL] [Abstract][Full Text] [Related]
37. A dose-response study to assess the renal hemodynamic, vascular, and hormonal effects of eprosartan, an angiotensin II AT1-receptor antagonist, in sodium-replete healthy men. Ilson BE; Boike SC; Martin DE; Freed MI; Zariffa N; Jorkasky DK Clin Pharmacol Ther; 1998 Apr; 63(4):471-81. PubMed ID: 9585802 [TBL] [Abstract][Full Text] [Related]
38. Evaluation of the 24-hour blood pressure effects of eprosartan in patients with systemic hypertension. White WB; Anwar YA; Mansoor GA; Sica DA Am J Hypertens; 2001 Dec; 14(12):1248-55. PubMed ID: 11775134 [TBL] [Abstract][Full Text] [Related]